Sarah Bos

130 CHAPTER 7 16. PotzeW, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JCM, et al. Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis. PLoS One. 2014 Feb;9(2):e88390. 17. Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, Sanyal AJ, et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;65(5):980–7. 18. Molinari M, Carrillo CF, Dongling D, Jorgensen D, Clemente-Sanchez A, Dharmayan S, et al. Portal Vein Thrombosis and Renal Dysfunction: A National Comparative Study of Liver Transplant Recipients for NAFLD versus Alcoholic Cirrhosis. Transpl Int. 2021;epub ahead of print. 19. Potze W, Siddiqui MS, Sanyal AJ. Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease. Semin Thromb Hemost. 2015;41(5):488–93. 20. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost. 2009;35(3):277–87. 21. Hylek EM, Hanna M, Al-khalidi HR, Ph D, Ansell J, Atar D, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–92. 22. Giugliano RP, Ruff CT, Braunwald E, Murphy, Sabina A, Wiviott, Stephen D, Halperin, Jonathan L, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. 23. Hacke W, Ph D, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–91. 24. Eikelboom J, Oldgren J, Ph D, Parekh A, Pogue J, Sc M, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart. N Engl J Med. 2009;361(12):1139–51. 25. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol. 2013;163(5):666–73. 26. Bos S, Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, et al. Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. Thromb Res. 2017;150:41–3. 27. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395–405. 28. Frost C, Yu Z, Wang J, Li T, Zeigler C, Schuster A, et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009;85(Suppl.1):S34 (PI-84). 29. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombingenerationmeasuredbymeans of calibrated automated thrombography(CAT). Thromb Haemost. 2006;95:772–5. 30. Wu J, Zhao HR, Zhang HY, Ge YL, Qiu S, Zhao JJZ, et al. Thrombin generation increasing with age and decreasing with use of heparin indicated by calibrated automated thrombogram conducted in Chinese. Biomed Environ Sci. 2014;27(5):378–84. 31. Schneider T, Siegemund T, Siegemund R, Petros S. Thrombin generation and rotational thromboelastometry in the healthy adult population. Hamostaseologie. 2015;35(2):181–6.